Pharmacokinetics and pharmacodynamics of multiple doses of BG00010, a neurotrophic factor with anti‐hyperalgesic effects, in patients with sciatica

Documenti analoghi

• First-In-Human, Double-Blind, Placebo-Controlled, Randomized, Dose-Escalation Study of BG00010, a Glial Cell Line-Derived Neurotrophic Factor Family Member, in Subjects with Unilateral Sciatica
  di: Rolan, Paul E., et al.
  Pubblicazione: (2015)
• Pharmacokinetics and pharmacodynamics of intrathecally administered Xen2174, a synthetic conopeptide with norepinephrine reuptake inhibitor and analgesic properties
  di: Okkerse, Pieter, et al.
  Pubblicazione: (2016)
• Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
  di: Hay, Justin L., et al.
  Pubblicazione: (2016)
• Population Pharmacokinetic/Pharmacodynamic Analysis of Nociceptive Pain Models Following an Oral Pregabalin Dose Administration to Healthy Subjects
  di: van Esdonk, Michiel J., et al.
  Pubblicazione: (2018)
• Population pharmacokinetic and pharmacodynamic analysis of BIIB023, an anti‐TNF‐like weak inducer of apoptosis (anti‐TWEAK) monoclonal antibody
  di: Galluppi, Gerald R., et al.
  Pubblicazione: (2016)